Herantis Pharma is an innovative biotech company developing disease-modifying therapies for Parkinson’s disease
Herantis Pharma Plc is an innovative biotech company developing disease-modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein.
Combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration
It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Disease-modifying therapy for Parkinson’s disease
Neurodegenerative diseases are characterized by complex pathology in the brain that results in progressive degeneration and, eventually death of neurons. In Parkinson’s disease, a specific type of neurons, the dopamine neurons of the nigrostriatal pathway located in the midbrain, are the cells that are primarily affected.
- The affected neurons play a central role in the coordination of motor functions. Typical symptoms of the disease are related to movement, such as tremor, slowness of movement, muscle stiffness and impaired balance. However, non-motor symptoms occur (e.g., problems with cognition, sleep, and speech; depression; severe constipation).
- Currently, available treatments can increase the dopamine levels in the brain and thereby alleviate motor symptoms. However, these treatments cannot stop or slow the progression of the disease, and the effect of these treatments will gradually be lost as an increasing amount of dopamine-producing neurons have degenerated.
